Skip to main content
News > News > Bacterial Robotics Announces Its Chief Consulting BactoBot Engineer

Bacterial Robotics Announces Its Chief Consulting BactoBot Engineer

Pablo Pomposiello, PhD, brings extensive bacterial engineering skills to Bacterial Robotics

CINCINNATI, OH, USA and MADRID, SPAIN. – December 28, 2012 – Bacterial Robotics, a synthetic biology company developing microscopic BactoBots™ announced the appointment of Pablo Pomposiello, PhD as its Chief Consulting BactoBot Engineer. BactoBots are organism-based programmable robots being deployed by go-to-market subsidiaries. Bacterial Robotics’ first subsidiary, Pilus Energy, is preparing to deploy RemediBots™ that clean industrial wastewater and GalvaniBots™ that clean industrial wastewater and in the process, generate electricity and gases.

Jason E. Barkeloo, Founder and CEO, Bacterial Robotics commented, “Dr. Pomposiello is an innovative scientist. His academic and professional bacterial experience well prepared him to lead the development and deployment of BactoBots.”

Among Dr. Pomposiello’s achievements are a PhD degree in Biology from the University of Michigan and a post-doctoral Fellowship at Harvard University. He became a professor at the Department of Microbiology at the University of Massachusetts, where he served for 8 years. He moved to Madrid and in 2011 founded Bacmine SL, a research and development company dedicated to synthetic biology. Dr. Pomposiello has more than 20 years of experience in microbiology, microbial genetics and the genetic engineering of bacteria. More on Dr. Pomposiello is HERE.

Dr. Pomposiello added, “Bacterial Robotics is pioneering a new way of doing biotech business, with a global scope and strong emphasis in engaging target markets. It is a pleasure to contribute to this innovative project.”

Barkeloo concluded, “Dr. Pomposiello distinguished himself during a global search as a can-do entrepreneurial scientist. He embraces our core philosophy of finding ways to get innovations done.”

*pdf version of this release

About Bacterial Robotics

An early developer in the emerging synthetic biology industry, Bacterial Robotics is headquartered in Cincinnati, Ohio (USA). The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system. The GeRM system is a consumable additive that prevents the BactoBots against theft and environmental release. The GeRM enables the Company to gain licensing revenues from the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to launch the product. Pilus Energy is the Company’s first subsidiary deploying the RemediBot™ that cleans industrial wastewater. Pilus Energy is also deploying the wastewater-to-value GalvaniBot™ that cleans wastewater and generates electricity and produces important gases.

For more information on Bacterial Robotics, visit its web site.


Jason E. Barkeloo
CEO +1.513.225.8765
Twitter: @BactoBot

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange